Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.78 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.78 |
| ▸ | MAOB | P27338 | 4/20 | 0.78 |
| ▸ | BCHE | P06276 | 3/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.78 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.78 |
| ▸ | ACHE | P22303 | 1/20 | 0.78 |
| ▸ | RECQL | P46063 | 1/20 | 0.78 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.78 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.73 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.73 |
| ▸ | RELA | Q04206 | 2/20 | 0.73 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.73 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.73 |
| ▸ | PKM | P14618 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL657748 | 1.00 | MAPT (0.78) | MAPTCYP1B1MAOBBCHELMNA | |
| SCHEMBL13680426 | 0.98 | CYP1B1 (0.81) | MAPTCYP1B1MAOBBCHELMNA | |
| SCHEMBL12306205 | 0.96 | CYP1B1 (0.71) | MAPTCYP1B1MAOBBCHELMNA | |
| SCHEMBL976912 | 0.96 | CYP1B1 (0.71) | MAPTCYP1B1MAOBBCHELMNA | |
| Chalcone SCHEMBL28027252 | 0.94 | CYP1B1 (0.88) | MAPTCYP1B1MAOBBCHELMNA | |
| SCHEMBL14045042 | 0.92 | CYP1B1 (0.78) | MAPTCYP1B1MAOBBCHELMNA | |
| SCHEMBL979407 | 0.92 | CYP1B1 (0.78) | MAPTCYP1B1MAOBBCHELMNA | |
| SCHEMBL9915665 | 0.92 | CYP1B1 (0.91) | MAPTCYP1B1MAOBBCHELMNA | |
| SCHEMBL8431772 | 0.92 | CYP1B1 (0.91) | MAPTCYP1B1MAOBBCHELMNA | |
| SCHEMBL12158776 | 0.91 | CYP3A4 (0.90) | MAPTCYP1B1MAOBBCHELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105367399-A | Preparing method of 9,10-phenanthraquinone compound | UNIV ZHEJIANG TECHNOLOGY | 2016-03-02 | — | — | CN | claimed |
| EP-0926951-B1 | TREATING PULMONARY DISEASES MEDIATED BY POLYUNSATURATED LIPID METABOLITES AND ASSAYS FOR EPOXIDE HYDROLASE INHIBITORS | UNIV CALIFORNIA (US) | 2004-04-21 | — | — | EP | claimed |
| CN-105367399-A | Preparing method of 9,10-phenanthraquinone compound | UNIV ZHEJIANG TECHNOLOGY | 2016-03-02 | — | — | CN | disclosed |
| EP-2349999-B1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIV SAARLAND (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8912186-B2 | Allosteric protein kinase modulators | UNIVERSITAET DES SAARLANDES (DE) | 2014-12-16 | — | — | US | disclosed |
| CN-103992356-A | Michael addition product of ferrocene-based chalcone and ethyl acetoacetate and preparation method thereof | UNIV SHAANXI SCIENCE & TECH | 2014-08-20 | — | — | CN | disclosed |
| US-20120046307-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIVERSITAET DES SAARLANDES (DE) | 2012-02-23 | — | — | US | disclosed |
| EP-2349999-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | Universität des Saarlandes (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-7872029-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP | 2011-01-18 | — | — | US | disclosed |
| WO-2010043711-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIVERSITAET DES SAARLANDES (DE) | 2010-04-22 | — | — | WO | disclosed |
| EP-2177510-A1 | Allosteric protein kinase modulators | Universität des Saarlandes (DE) | 2010-04-21 | — | — | EP | disclosed |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Robinson, Thomas Philip (US) | 2009-01-15 | — | — | US | disclosed |
| US-7432303-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Bowen, J. Phillip (US) | 2008-10-07 | — | — | US | disclosed |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2005-07-07 | — | — | US | disclosed |
| US-6906105-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP (US) | 2005-06-14 | — | — | US | disclosed |
| US-20030027830-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2003-02-06 | — | — | US | disclosed |
| US-6462075-B1 | USE OF CHALCONE AND ITS DERIVATIVES AS ANTITUMOR/ANTICANCER AGENTS AND TO TREAT A NUMBER OF CONDITIONS OR DISEASE STATES IN WHICH ANGIOGENESIS IS A FACTOR INCLUDING PSORIASIS, ACNE, ROSACEA, WARTS, ECZEMA, HEMANGIOMAS AND LYMPHANGIOGENESIS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2002-10-08 | — | — | US | disclosed |
| EP-1242352-A2 | CHALCONE AND ITS ANALOGS AS AGENTS FOR THE INHIBITION OF ANGIOGENESIS AND RELATED DISEASE STATES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN, J. PHILLIP | 2002-04-04 | — | — | US | disclosed |
| WO-2001046110-A2 | CHALCONE AND ITS ANALOGS AS AGENTS FOR THE INHIBITION OF ANGIOGENESIS AND RELATED DISEASE STATES | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | MAPT 1111/4885CYP1B1 780/4885MAOB 2579/4885 |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | MAPT 1274/4885CYP1B1 747/4885MAOB 2526/4885 |
| US-20030027830-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | MAPT 341/4885CYP1B1 604/4885MAOB 1509/4885 |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | MAPT 341/4885CYP1B1 604/4885MAOB 1509/4885 |
| US-20120046307-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | AURKC, AURKA, AURKB | MAPT 964/4885CYP1B1 4714/4885MAOB 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.